The calcium antagonist controversy: The emerging importance of drug formulation as a determinant of risk

American Journal of Cardiology

Volumn 79, Issue 10 A, 1997, Pages 9-19

  Epstein, Murray ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CONFERENCE PAPER; DRUG EFFECT; DRUG FORMULATION; HUMAN; HYPERTENSION; PRIORITY JOURNAL;

CALCIUM CHANNEL BLOCKERS; CHEMISTRY, PHARMACEUTICAL; FORMULARIES; HEART DISEASES; HEMODYNAMIC PROCESSES; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 0030737879     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00266-X     Document Type: Conference Paper

References (72)

1. Epstein M. Calcium antagonists in the management of hypertension. Epstein M. Calcium Antagonists in Clinical Medicine. 1992;213-230 Hanley and Belfus, Philadelphia.
2. Frishman WH. Current status of calcium channel blockers. Curr Prob Cardiol. 19:1994;637-688.
3. Epstein M. Calcium antagonists and renal protection: current status and future perspectives. Arch Intern Med. 152:1992;1573-1584.
4. Messerli FH, McLoughlin M. Cardiac effects of calcium antagonists in hypertension. Epstein M. Calcium Antagonists in Clinical Medicine. 1992;137-150 Hanley and Belfus, Philadelphia.
5. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens. 9:1996;695-699.
6. Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR. Calcium channel blockade and incidence of cancer in aged populations. Lancet. 348:1996;493-497.
7. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview of the result from the randomized trials. BMJ. 299:1989;1187-1192.
8. Furberg CD, Psaty BM. Calcium antagonists: not appropriate as first line antihypertensive agents. Am J Hypertens. 9:1996;122-125.
9. Angell M. Science on Trial. 1996;WW Norton and Company, New York.
10. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction: a hypothesis formulated but not yet tested. JAMA. 274:1995;654-655.
11. Opie LH, Messerli FH. Nifedipine and mortality. Grave defects in the dossier. Circulation. 92:1995;1068-1073.
12. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Ragunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 274:1995;620-625.
13. Epstein M. Calcium antagonists should continue to be used for first-line treatment of hypertension. Arch Intern Med. 155:1995;2150-2156.
14. Epstein M. Calcium antagonists: still appropriate as first-line antihypertensive agents. Am J Hypertens. 9:1996;110-121.
15. Morris AD, Meredith PA, Reid JL. Pharmacokinetics of calcium antagonists: implications for therapy. Epstein M. Calcium Antagonists in Clinical Medicine. 1992;49-67 Hanley and Belfus, Philadelphia.
16. Triggle DJ. Biochemical and pharmacologic differences among calcium channel antagonists: clinical implications. Epstein M. Calcium Antagonists in Clinical Medicine. 1992;1-27 Hanley and Belfus, Philadelphia.
17. Ruzicka M, Leenen FHH. Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists. Laragh JH, Brenner BM. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd Ed. 1995;2815-2825 Raven Press, New York.
18. Kleinbloesem CH, van Brummelen P, Danlöf M, Faber H, Urquhart J, Breimer DD. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther. 41:1987;26-30.
19. Myers MG, Raemsch KD. Comparative pharmacokinetics and antihypertensive effects of the nifedipine tablet and capsule. J Cardiovasc Pharmacol. 10:((suppl 10)):1987;S76-S78.
20. Swanson DR, Barclay BL, Wong PSL, Theeuwes F. Nifedipine gastrointestinal therapeutic system. Am J Med. 83:((suppl 6B)):1987;3-9.
21. Chung M, Reitberg DP, Gafney M, Singleton W. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled release formulation of nifedipine. Am J Med. 83:((suppl 6B)):1987;10-14.
22. Stokes GS, Shenfield GM, Johnston HJ, Marwood JF, Dunagan F, Boutagy J. Timing of blood pressure measurements in determining anomalies in duration of effect of an antihypertensive drug: assessment of isradipine. J Cardiovasc Pharmacol. 15:((suppl 1)):1990;S65-S69.
23. Frohlich ED, McLoughlin MJ, Losem CJ, Ketelhut R, Messerli FH. Hemodynamic comparison of two nifedipine formulations in patients with essential hypertension. Am J Cardiol. 68:1991;1346-1350.
24. Rousseau MF, Melin J, Benedict CR, Ahn S, Raphael D, Bornemann M, Pouler H. Effects of nisoldipine therapy on myocardial perfusion and neuro-hormonal status in patients with severe ischaemic left ventricular dysfunction. Eur Heart J. 15:1994;957-964.
25. Bond G, Del Palu C, Hansson L, Magnani B, Giuseppe M, Neiss A, Rahn KH, Reid JL, Rodicio JL, Safar M, Zanchetti A. ELSA: European Lacidipine Study on Atherosclerosis. (Abstr.). J Hypertens. 11:((suppl 5)):1993;S405.
26. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, Kappagoda T, Rocco MV, Schnaper HW, Sowers JR, Bond G. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA. 276:1996;785-791.
27. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target organ damage in hypertension. J Hypertens. 5:1987;93-98.
28. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens. 11:1993;1133-1137.
29. Billman GE. The antiarrhythmic effects of calcium antagonists. Epstein M. Calcium Antagonists in Clinical Medicine. 1992;183-212 Hanley and Belfus, Philadelphia.
30. Chakko S, Bassett AL. Are calcium antagonists proarrhythmic? Epstein M. Calcium Antagonists in Clinical Medicine. 2nd Ed. 1997;Hanley and Belfus, Philadelphia.
31. Roine RO, Kaste M, Kinnunen A, Nikki P, Sarna S, Kajaste S. Nimodipine after resuscitation from out of hospital ventricular fibrillation. JAMA. 264:1990;3171-3177.
32. Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Circulation. 84:1991;2598-2600.
33. Egstrup K, Andersen PE. Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol. Am J Cardiol. 71:1993;177-183.
34. Schulz W, Jost S, Kober G, Kaltenbach M. Relation of antianginal efficacy of nifedipine to degree of coronary arterial narrowing and to presence of coronary collateral vessels. Am J Cardiol. 55:1985;26-32.
35. Kloner RA. Nifedipine in ischemic heart disease. Circulation. 92:1995;1074-1078.
36. Malacoff RF, Lorell BH, Mudge GH, Holman BL, Idoine J, Bifolck L, Cohn PF. Beneficial effects of nifedipine on regional myocardial blood flow in patients with coronary artery disease. Circulation. 65:((suppl I)):1982;I-32-I-37.
37. Kugiyama K, Yasue H, Horio Y, Morikami Y, Fujii H, Koga Y, Kojima A, Takahashi M. Effects of propranolol and nifedipine on exercise thallium-201 myocardial scintigraphy with quantitative rotational tomography. Circulation. 2:1986;374-380.
38. Bonaduce D, Muto P, Morgano G, Cononico V, Breglio R, Salvatore M, Condorelli M. Effect of nifedipine on dipyridamole thallium-201 myocardial scintigraphy. Clin Cardiol. 9:1986;285-288.
39. Hayward R, Hunter GJS, Swanton H. Effects of nifedipine on coronary perfusion: recent assessment by parametric digital subtraction. Eur Heart J. 8:((suppl k)):1987;1-7.
40. Nesto RW, White HD, Ganz P, Koslowski J, Wynne J, Holman BL, Antman E. Addition of nifedipine to maximal beta-blocker nitrate therapy: effects on exercise capacity and global left ventricular performance at rest and during exercise. Am J Cardiol. 55:1985;3E-8E.
41. Parmley WW, Nesto RW, Singh BN, Deanfield J, Gottlieb SO. Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina. J Am Coll Cardiol. 19:1992;1380-1389.
42. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, et al. Prospective Randomized Amlodipine Survival Evaluation Study Group (PRAISE). Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 335:1996;1107-1114.
43. Gong L, Zhang W, Zhu Y, Zhu J. 11 collaborating centres in the Shanghai area, Kong D, Page V, Ghadirian P, LeLorier J, Hamet P. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 14:1996;1237-1245.
44. Cohn JN, Ziesche SM, Loss LE, Anderson GF. Effect of felodipine on short term exercise and neurohormone and long term mortality in heart failure: results of VHeFT III. Circulation. 92:1995;I-143.
45. Poole-Wilson PA. Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Eur Heart J. 18:1997;31-40.
46. Kloner RA, Vetrovec G. Long-acting calcium channel blockers nifedipine GITS and amlodipine in hypertension. Rate of myocardial infarction. (Abstr.). J Am Coll Cardiol. 27:((suppl A)):1996;177A.
47. Abascal VM, Larson MG, Evans JC, Poll KA, Levy D. Calcium channel blocker use is not associated with increased mortality. (Abstr.). Circulation. 94:((suppl 1)):1996;3383.
48. Connor J, Sawczuk IS, Benson MC, Tomashefsky P, O'Toole KM, Olsson CA, Buttyan R. Calcium channel antagonists delay regression of androgen dependent tissues and suppress gene activity associated with cell death. Prostate. 13:1988;119-130.
49. 2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J. 7:1993;453-463.
50. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet. 341:1993;1251-1254.
51. Trump BF, Berezesky IK. Calcium mediated cell injury and cell death. FASEB J. 9:1995;219-228.
52. Martin SJ, Green DR. Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol Hematol. 18:1995;137-153.
53. Whitfield JF. Calcium signals and cancer. Crit Rev Oncol. 3:1992;55-90.
54. Garland C, Shekelle RB, Barrett Connor E, Criqui MH, Rossof AH, Paul O. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet. i:1985;307-309.
55. Dargie HJ. Calcium channel blockers and the clinician. Lancet. 348:1996;488-489.
56. Zacharski LR, Moritz TE, Haakenson CM, O'Donnell JF, Ballard HS, Johnson GJ, Ringenberg QS, Schilsky RL, Spaulding MB, Tornyosk K, Williams CC. Chronic calcium antagonist use in carcinoma of the lung and colon: a retrospective cohort observational study. Cancer Invest. 8:1990;451-459.
57. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 304:1992;405-412.
58. Hole DJ, Hawthorne VM, McGhee SM, Robertson JW, Gillis CR, Wapshaw JA, Lever AF. Incidence of mortality from cancer in hypertensive patients. BMJ. 306:1993;609-611.
59. Taubes G. Epidemiology faces its limits. Science. 269:1995;164-169.
60. Rauwolfia derivatives and cancer. Lancet. ii:1974;701-702.
61. Reserpine and breast cancer. Lancet. ii:1974;669-671.
62. Shapiro S, Parsells JL, Rosenberg L, Kaufman DW, Stolley PD, Schottenfeld D. Risk of breast cancer in relation to the use of rauwolfia alkaloids. Eur J Clin Pharmacol. 26:1984;143-146.
63. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 25:1995;305-313.
64. Frohlich ED. There is good news and not so good news. (Editorial). Hypertension. 25:1995;303-304.
65. Cardiomonitor 1992. Hosie J, Wiklund I. Managing hypertension in general practice: can we do better? Hum Hypertens. 9:1995;S15-S18.
66. Neaton JD, Grimm RH Jr., Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonald R, Lewis CE, Liebson PR. Treatment of Mild Hypertension Study. JAMA. 270:1993;713-724.
67. Elliot WJ. Drug therapy and "dropouts" in a tertiary hypertension clinic. (Abstr.). Am J Hypertens. 7:1994;26A.
68. Cushman WC. The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Design and initial characteristics. (Abstr.). Hypertension. 25:1995;1356.
69. Brown MJ, Castaigne A, Ruilope LM, Mancia G, Rosenthal T, de Leeuw PW, Ebner F. INSIGHT: International nifedipine GITS study intervention as a goal in hypertension treatment. J Hum Hypertens. 10:((suppl 3)):1996;S157-S160.
70. Dahlöf B, Hansson L, Lindholm LH, Schersten B, Webster PO, Ekbom T, Hedner T, De Faire U. STOP Hypertension 2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Press. 2:1993;136-141.
71. Warram JH, Laffel LMB, Valsania P, Christlieb AR, Krolewski AS. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med. 151:1991;1350-1356.
72. National high blood pressure education program working group report on hypertension in diabetes. Hypertension. 23:1994;145-158.